Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
Massachusetts General Hospital
90 participants
Dec 30, 2022
INTERVENTIONAL
Conditions
Summary
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.
Eligibility
Inclusion Criteria4
- Age 18 years or older.
- Ability to complete surveys in English or with assistance of an interpreter.
- Diagnosis of a hematologic malignancy.
- Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.
Exclusion Criteria2
- Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
- Already receiving palliative care (PC).
Interventions
* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers. * Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care. * The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot.
Standard care for ACT per the treating team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05646576